Comparative Pharmacology
Head-to-head clinical analysis: CUPRIMINE versus PENICILLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIMINE versus PENICILLAMINE.
CUPRIMINE vs PENICILLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
None Documented
None Documented
Clinical Note
moderatePenicillamine + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Iron
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Category C
Category C
Chelating Agent
Chelating Agent
"Penicillamine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy."